- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01232504
Antifugal Effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) in Patients Post Allo-HSCT
October 27, 2014 updated by: Xiamen Amoytop Biotech Co., Ltd.
Effect of Granulocyte-macrophage Stimulating Factor on Prevention and Treatment of Invasive Fungal Diseases in the Recipients of Allogeneic Stem Cell Transplantation: A Prospective Multicenter Randomized Phase 4 Trial
We conducted a prospective, multicenter, open-label randomized trial to compare the antifungal effect of Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF), Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) or a combination of rhGM-CSF and rhG-CSF for neutropenic patients undergoing allogeneic stem cell transplantation.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
From Sept 2009 to Dec 2012, we recruited consecutive patients with hematological diseases undergoing allogeneic stem cell transplantation at 5 institutions in China.
Recipients between ages of 14 to 60 years old were eligible.
Eligible patients were randomized to receive once daily subcutaneous 5-7μg/kg/d GM-CSF (Molgramostim, TOPLEUCON®; Xiamen Amoytop Biotech Co., Ltd., China) (GM-CSF group), 5-7μg/kg/d G-CSF (G-CSF group), or a combination of 2-3μg/kg/d GM-CSF and 2-3μg/kg/d G-CSF each (G-CSF+GM-CSF group).
Administration of CSFs was started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
If absolute neutrophil count (ANC) decreased to < 1.5×10(9)/L within 5 days after withdrawal of CSFs, the same CSF would be resumed until the absolute neutrophil count (ANC) reached 1.5×10(9)/L again.
All patients received antimicrobial prophylaxis with oral levofloxacin 500 mg daily and antifungal prophylaxis with oral fluconazole 200 mg daily.
Study Type
Interventional
Enrollment (Actual)
206
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Guangxi
-
Nanning, Guangxi, China, 530021
- The First Affiliated Hospital of Guangxi Medical University
-
-
Henan
-
Zhengzhou, Henan, China, 450003
- Henan Cancer Hospital
-
-
Hubei
-
Wuhan, Hubei, China, 430030
- Wuhan Tongji Hospital
-
-
Shanghai
-
Shanghai, Shanghai, China, 200080
- Shanghai First People's Hospital
-
-
Xinjiang
-
Urumqi, Xinjiang, China, 830054
- The First Affiliated Hospital of Xinjiang Medical University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 14~60 years old
- Allogenic hematological stem cell transplantation(HSCT) patients.
- Cardiac ejection factor ≥ normal upper limit, Aspartate aminotransferase and/or Alanine aminotransferase < 2 upper limit of normal, and/or total bilirubin < 2.5 upper limit of normal, creatinine < upper limit of normal.
- Informed consent.
Exclusion Criteria:
- Evidence of proven, probable or possible fungal infection at the time of enrollment.
- Patients were receiving anti-fungal treatment with proven SFI before transplantation.
- A history of hypersensitivity to G-CSF or GM-CSF.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rhGM-CSF group
subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) once daily
|
subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
Other Names:
|
Active Comparator: rhG-CSF+rhGM-CSF group
a combination of 2-3μg/kg/d Recombinant Human Granulocyte-macrophage Stimulating Factor (rhGM-CSF) and 2-3μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) each
|
a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
Other Names:
|
Active Comparator: rhG-CSF group
subcutaneous 5-7μg/kg/d Recombinant Human Granulocyte Stimulating Factor (rhG-CSF) once daily
|
subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidences of Invasive Fungal Diseases (IFD)
Time Frame: 100 day post transplant
|
The incidence of proven and probable Invasive fungal diseases (IFD) within 100 days post transplantation
|
100 day post transplant
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Hematological Engraftment
Time Frame: 100 days post transplant
|
The median time of neutrophil and platelet recovery .
|
100 days post transplant
|
Transplant Related Mortality
Time Frame: 100 days post transplant
|
Transplant related mortality within 100 days after Allogeneic Stem Cell Transplantation (Allo-HSCT).
|
100 days post transplant
|
Incidence of Ⅱ- Ⅳ Acute Graft Versus Host Disease (aGVHD)
Time Frame: 100 days post transplant
|
Incidence of Ⅱ- Ⅳacute graft versus host disease (aGVHD) within 100 days after allogeneic stem cell transplantation (Allo-HSCT).The severity of acute GVHD in the three main target organs (skin, liver, gastrointestinal tract) was assigned stage 1 to 4 based on accepted criteria (Consensus Conference on Acute GVHD Grading).
|
100 days post transplant
|
IFD Related Mortality
Time Frame: 3-1099 days
|
IFD-related mortalities after a median follow-up of 600 days.
|
3-1099 days
|
Relapse Related Mortality
Time Frame: 3~1099 days
|
Relapse related mortality after a median follow-up of 600 days.
|
3~1099 days
|
Graft Versus Host Disease (aGVHD) Related Mortality
Time Frame: 3-1099 days
|
Graft versus host disease (aGVHD) related mortality after a median follow-up of 600 days .
|
3-1099 days
|
Hemorrhage Related Mortality
Time Frame: 3-1099 days
|
Hemorrhage related mortality after a median follow-up of 600 days
|
3-1099 days
|
Infection Related Mortality
Time Frame: 3~1099 days)
|
Infection related mortality after a median follow-up of 600 days.
|
3~1099 days)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Chun Wang, M.D., Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2009
Primary Completion (Actual)
March 1, 2013
Study Completion (Actual)
June 1, 2013
Study Registration Dates
First Submitted
October 25, 2010
First Submitted That Met QC Criteria
October 31, 2010
First Posted (Estimate)
November 2, 2010
Study Record Updates
Last Update Posted (Estimate)
November 4, 2014
Last Update Submitted That Met QC Criteria
October 27, 2014
Last Verified
October 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- L-09-01
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Mycoses
-
Steven B. KleiboekerNational Institute of Allergy and Infectious Diseases (NIAID)WithdrawnAdenovirus | Other MycosesUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
Fungal Infection Study ForumMerck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Institut National de la Santé Et de la Recherche...UnknownCandidiasisBelgium, France, Italy, Netherlands, Spain
-
PfizerVicuron PharmaceuticalsCompleted
-
Daniel BenjaminEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompletedFluconazole Prophylaxis for the Prevention of Candidiasis in Infants Less Than 750 Grams BirthweightCandidiasisUnited States
-
Merck Sharp & Dohme LLCCompleted
-
Universitaire Ziekenhuizen KU LeuvenCompleted
Clinical Trials on rhGM-CSF group
-
GeneScience Pharmaceuticals Co., Ltd.Third Military Medical University; Shanghai Jiao Tong University School of... and other collaboratorsCompletedDeep Partial Thickness Burn
-
University of Wisconsin, MadisonUnited States Department of DefenseCompletedProstate CancerUnited States
-
Peking University Cancer Hospital & InstituteCompletedLung Cancer MetastaticChina
-
The Affiliated Hospital of the Chinese Academy...Unknown
-
Shanghai Cancer Hospital, ChinaNot yet recruitingThymic Epithelial TumorChina
-
University of Wisconsin, MadisonDendreonCompletedProstate CancerUnited States
-
Reponex Pharmaceuticals A/SActive, not recruiting
-
University of Wisconsin, MadisonMadison Vaccines IncorporatedCompletedProstate CancerUnited States
-
University of Wisconsin, MadisonCompletedProstate CancerUnited States
-
University of GiessenCompleted